<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978385/" ref="ordinalpos=2465&amp;ncbi_uid=6006523&amp;link_uid=PMC3978385" image-link="/pmc/articles/PMC3978385/figure/F4/" class="imagepopup">Figure 4. Transactivation of Raf <span class="highlight" style="background-color:">signaling</span> by BRAF inhibitors in Ras mutant melanoma.  From: NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. </a></div><br /><div class="p4l_captionBody"><b>A.</b> Typically, NRAS mutant melanomas rely on CRAF-mediated MAPK activation, with BRAF locked into an inactive conformation. <b>B.</b> BRAF inhibitors relieve the auto-inhibition of BRAF leading to its recruitment to the plasma membrane. This then leads to the dimerization of BRAF and CRAF leading to enhanced MAPK pathway signaling and proliferation.</div></div>